## CORRECTED VERSION

#### (19) World Intellectual Property Organization International Bureau



# 

#### (43) International Publication Date 26 February 2004 (26.02.2004)

### (10) International Publication Number WO 2004/016578 A3

- (51) International Patent Classification7: C07C 217/10. 311/29, 213/00, 303/40, C07D 215/26, 213/65, 265/36, 277/68
- (21) International Application Number:

PCT/EP2003/008264

- (22) International Filing Date: 24 July 2003 (24.07.2003)
- (25) Filing Language:

(26) Publication Language:

English

(30) Priority Data:

0217225.2

25 July 2002 (25.07.2002)

- (71) Applicant (for all designated States except US): GLAXO GROUP LIMITED [GB/GB]; Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): BIGGADIKE, Keith [GB/GB]; GlaxoSmithKline, Gunnels Wood Road. Stevenage, Hertfordshire SG1 2NY (GB). COE, Diane, Mary [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). HOLMES,

Duncan, Stuart [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY (GB). LOOKER, Brian, Edgar [GB/GB]; GlaxoSmithKline, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY

- (74) Agent: FLORENCE, Julia, Anne; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford, Middlesex TW8 9GS (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM). European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

(54) Title: ARYLETHANOLAMINE BETA2-ADRENORECEPTOR AGONIST COMPOUNDS

tives thereof, wherein: R1 is hydrogen or -XSO2NR6R7; R2 and R3 are independently selected from hydrogen, C1-6 alkyl, C1-6 alkoxy, halo, phenyl and C<sub>1.6</sub> haloalkyl and Ar is a group selected from and. Processes for preparing said compounds and pharmaceutical formulations containing them are also described. Compounds of formula (I) are useful in the treatment of respiratory diseases

SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- with international search report
- (88) Date of publication of the international search report: 10 June 2004
- (48) Date of publication of this corrected version: 17 February 2005
- (15) Information about Correction: see PCT Gazette No. 07/2005 of 17 February 2005, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.